Viable Pregnancy in a patient with metastatic melanoma treated with double checkpoint immunotherapy

Area of Science:

• Oncology
• Immunology
• Maternal-Fetal Medicine

Background:

• Metastatic cancers in pregnancy present treatment challenges due to limited options and historically poor outcomes.
• Immune checkpoint inhibitors (ICIs) have revolutionized metastatic cancer treatment but raise concerns during pregnancy.
• Pregnancy involves immune tolerance mechanisms, and ICI use may interfere, potentially increasing miscarriage risk.

Observation:

• A 7-week pregnant patient diagnosed with metastatic melanoma was treated with nivolumab plus ipilimumab.
• The case details immune-related adverse events and their management.
• The study documents the oncologic and pregnancy outcomes following this novel treatment approach.

Findings:

• Combined immunotherapy with nivolumab and ipilimumab was successfully administered to a pregnant patient with metastatic melanoma.
• Management strategies for immune-related adverse events were effective.
• The treatment led to a favorable oncologic response and a positive pregnancy outcome.

Implications:

• This case suggests that combined immunotherapy may be a viable treatment option for select pregnant patients with metastatic melanoma.
• Further research is warranted to evaluate the safety and efficacy of ICIs in pregnancy.
• Understanding the interplay between ICIs, pregnancy, and immune tolerance is crucial for optimizing patient care.